Resistência medicamentosa múltipla secundária na hanseníase
DOI:
https://doi.org/10.47878/hi.1993.v18.35466Keywords:
Secondary multidrug resistanceAbstract
Four patients with leprosy bacilli secondarily to two and three drugs of WHO-MDT are reported. The authors discuss the way of appearance of this multidrug resistance and the possibility of its primary occurrence. They remind what is happening in US regarding tuberculosis where cases with initial multidrug resistance has been shown, probably in most cases due to AIDS and admit the risk of the appearance of this same situation in leprosy. Finally, they warn to the undue use of new drugs, easily available in pharmacies, which are yet under experiment for leprosy treatment.
Downloads
Download data is not yet available.
References
1. BAOHONG, J. Drug resistance in leprosy. A review. Leprosy Rev., 56: 265-78, 1985.
2. BAOHONG, J. ;JIAKUN, C.; JIALIN, Z.; YUHONG, H.; GUOXING, N. & RENBAC, Z. Secondary dapsone resistant leprosy in Shangai municipality. Leprosy Rev., 54:197-202, 1983.
3. BAQUILON, G.; FERRACI, C.; VAN LOO, G. & PATTYN, S.R. Further results on dapsone resistant leprosy en Bamako (Mali). Leprosy Rev., 56:265-78, 1983.
4. DAMASCO, M.H.S.; TALHARI, S.; VIANA, S.M.; SIGNORELLI, M.; SAAD, M.H.F. & ANDRADE, L.M.C. Secondary dapsoneresistant leprosy en Brazil. A preliminaryreport. Leprosy Rev. 51: 5-8, 1986.
5. GUINTO, S.R.; CELLONA, R.V.; FAJARDO, T.T. & Cruz, E.D. de la. Primary dapsoneresistant leprosy in Cebu, Philippines. Int. J. Leprosy, 49: 427-39, 1981.
6. JACOBSON, R.R. Rifampin-resistant leprosy. Lancet, 2 1304-05, 1976.
7. WARNDORFF-VAN DIEPEN, T. Clofazimineresistant leprosy, a case report. Int J. Leprosy, 5U 139-42, 1982.
8. WORLD HEALTH ORGANIZATION STUDY GROUP. Chemotherapy of leprosy for control programs. WHO technical report secies 675: Geneva,1982.
9. FREIDEN ET AL. The emergence of Drugresistant tuberculosis in New York city. The New England Journal of Medicine vol.328 nº 8, February 25,1993.
10. GOBLE ET AL. Treatment of 171 patients with pulmonarytuberculosis resistantto ioniazid and rifampin. The New England Journal
of Medicine.
11. NOORDEN, S.K. Wordlwide Implementation of WHO/MDT and Experiences Gained. Paper for Conference on Chemotherapy of Leprosy, Greenville, 6-8 April, 1992.
2. BAOHONG, J. ;JIAKUN, C.; JIALIN, Z.; YUHONG, H.; GUOXING, N. & RENBAC, Z. Secondary dapsone resistant leprosy in Shangai municipality. Leprosy Rev., 54:197-202, 1983.
3. BAQUILON, G.; FERRACI, C.; VAN LOO, G. & PATTYN, S.R. Further results on dapsone resistant leprosy en Bamako (Mali). Leprosy Rev., 56:265-78, 1983.
4. DAMASCO, M.H.S.; TALHARI, S.; VIANA, S.M.; SIGNORELLI, M.; SAAD, M.H.F. & ANDRADE, L.M.C. Secondary dapsoneresistant leprosy en Brazil. A preliminaryreport. Leprosy Rev. 51: 5-8, 1986.
5. GUINTO, S.R.; CELLONA, R.V.; FAJARDO, T.T. & Cruz, E.D. de la. Primary dapsoneresistant leprosy in Cebu, Philippines. Int. J. Leprosy, 49: 427-39, 1981.
6. JACOBSON, R.R. Rifampin-resistant leprosy. Lancet, 2 1304-05, 1976.
7. WARNDORFF-VAN DIEPEN, T. Clofazimineresistant leprosy, a case report. Int J. Leprosy, 5U 139-42, 1982.
8. WORLD HEALTH ORGANIZATION STUDY GROUP. Chemotherapy of leprosy for control programs. WHO technical report secies 675: Geneva,1982.
9. FREIDEN ET AL. The emergence of Drugresistant tuberculosis in New York city. The New England Journal of Medicine vol.328 nº 8, February 25,1993.
10. GOBLE ET AL. Treatment of 171 patients with pulmonarytuberculosis resistantto ioniazid and rifampin. The New England Journal
of Medicine.
11. NOORDEN, S.K. Wordlwide Implementation of WHO/MDT and Experiences Gained. Paper for Conference on Chemotherapy of Leprosy, Greenville, 6-8 April, 1992.
Downloads
Published
1993-11-30
How to Cite
1.
OPROMOLLA DVA, COSTA HC, OLIVEIRA PRD de. Resistência medicamentosa múltipla secundária na hanseníase. Hansen. Int. [Internet]. 1993 Nov. 30 [cited 2024 May 16];18(1/2):11-6. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35466
Issue
Section
Original articles
License
This journal is licensed under a Creative Commons Attribution 4.0 International License.
